We are live on ! Find out more
ACM

AIHC Capital Management Portfolio holdings

AUM $104M
This Fund
S&P 500
This Quarter Est. Return
+58.21%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$107M
AUM Growth
Cap. Flow
+$93.3M
Cap. Flow %
87.48%
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.6B
$71.7M 67.21%
+900,392
New +$59M
PTGX icon
2
Protagonist Therapeutics
PTGX
$9.34B
$16.6M 15.54%
+189,823
New +$15.5M
AVBP icon
3
ArriVent BioPharma
AVBP
$1.49B
$13M 12.16%
+644,788
New +$13.4M
COGT icon
4
Cogent Biosciences
COGT
$6.02B
$3.55M 3.33%
+100,000
New +$2.81M
NBP
5
NovaBridge Biosciences American Depositary Shares
NBP
$213M
$1.65M 1.54%
+413,979
New +$1.83M
KRRO icon
6
Korro Bio
KRRO
$190M
$242K 0.23%
+30,265
New +$707K

Similar funds

AIHC Capital Management's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for AIHC Capital Management, which disclosed 6 positions worth $107M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Revolution Medicines: 900,392 shares worth $71.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • AIHC Capital Management's largest Q4 2025 buy was Revolution Medicines: 900,392 shares worth $71.7M.
  • AIHC Capital Management's ten largest holdings make up 100% of its $107M portfolio in Q4 2025.
  • AIHC Capital Management disclosed 6 positions in Q4 2025, its first 13F filing on record.

Based on AIHC Capital Management's 13F filing for Q4 2025, filed 5 Feb 2026.